Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers.

Atukorale, Prabhani U; Moon, Taylor J; Bokatch, Alexandr R; Lusi, Christina F; Routhier, Jackson T; Deng, Victoria J; Karathanasis, Efstathios

Atukorale, Prabhani U; Moon, Taylor J; Bokatch, Alexandr R; Lusi, Christina F; Routhier, Jackson T; Deng, Victoria J; Karathanasis, Efstathios.

Afiliação

Atukorale PU; Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. stathis@case.edu.
Moon TJ; Case Comprehensive Cancer Center, Cleveland, OH 44106, USA.
Bokatch AR; Department of Biomedical Engineering, University of Massachusetts, Amherst, MA 01003, USA.
Lusi CF; Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. stathis@case.edu.
Routhier JT; Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. stathis@case.edu.
Deng VJ; Department of Biomedical Engineering, University of Massachusetts, Amherst, MA 01003, USA.
Karathanasis E; Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. stathis@case.edu.

Nanoscale ; 14(4): 1144-1159, 2022 Jan 27.

Article em En | MEDLINE | ID: mdl-35023530

Assuntos

Nanopartículas; Neoplasias; Animais; Linfócitos T CD8-Positivos; Imunização; Imunoterapia; Camundongos; Terapia Neoadjuvante

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Nanopartículas / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nanoscale Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google